Alzheimer’s drugs: Lecanemab and donanemab to be reconsidered for NHS after appeal

BMJ 2026

View at publisher

Authors: Gareth Iacobucci

DOI: 10.1136/bmj.s551

Cited by: 4

References: 4

Fields of Study & Subjects

Healthcare Systems and Challenges Health Services Management and Policy Pharmacological Receptor Mechanisms and Effects

References 4